DGAP-News: curasan returns to growth with a 16 percent increase in sales compared to previous year's quarter

- Net Group sales in the first half of the year at EUR 3.4 million, at the previous year's level

- Strengthened partner base continues to materialize with growth of +20 % in German and +50 % in Asian market

- Guidance for full year 2018 confirmed

Kleinostheim, 23 August 2018 - curasan AG (ISIN DE0005494538), a leading specialist in medical products in the field of orthobiologics, returned to its growth path in the second quarter of 2018. Overall, sales in the first half of the year were at the previous year's level. After the subdued development in the first quarter, however, a significant increase in momentum and a significant increase in sales are now apparent again.

Net sales reached EUR 3.4 million in the reporting period (H1 2017: EUR 3.4 million), but grew by a good 16 percent compared with the second quarter of 2017 and around 22 percent compared to the first quarter of 2018 and can thus be seen again to meet the long-term growth targets. Earnings before interest, taxes, depreciation and amortization (EBITDA) was also at the previous year's level at EUR -1.2 million (H1 2017: EUR -1.2 million). On the other hand, the net result was much better at -1.5 million euro (H1 2017: -2.0 million euro). The company once again invested heavily in sales and product registrations, especially in the US focus market.

"In the last three months, we have grown again and were able to build on stable partners, especially in Germany and Asia, which is a very positive signal and encourages us on our way," said Michael Schlenk, CEO of curasan AG. "In the current fiscal year, we remain focused on securing further strong strategic partners. In addition, the launch of spinal products in the US market, planned for the fourth quarter, will further fuel our growth. "

Sales in the German market grew by around 22 percent in the first half of the year, which was reflected in stable export sales and an export quota of 77 percent compared with 81 percent in the same period of the previous year. With increases of more than 50 percent to EUR 1.0 million (H1 2017: 0.7 mEUR) in the Asia focus region, it was possible to materialize the strategic approaches and investments from 2017. In contrast, sales in the Middle East region declined, which is largely due to the difficult economic and political conditions. The European markets and America remained largely stable, especially in the US, where we expect product-driven significant growth only in the fourth quarter.

Against the backdrop of the first half of the year being in line with expectations and the expected development in the further course of the year, the Management Board remains unchanged in its guidance for the development of sales and earnings for the current financial year 2018.

In July, curasan announced the implementation of a capital increase. The transaction was successfully completed at the end of July with a nominal volume of EUR 1,141,754.00.

curasan has made the full report for the first half year of 2018 available on the company's website under the following link: www.curasan.com/investors/publications/financial-reports.

Contact curasan AG:

Andrea Weidner
Head of Investor Relations & Corporate Communications
+49 6027 40 900-51
andrea.weidner@curasan.com

About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan.

curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange (ISIN: DE0005494538).